Get the Stockscreener App
1.11
0.89%
-0.01
After Hours:
1.13
0.02
+1.80%
Actinium Pharmaceuticals Inc stock is traded at $1.11, with a volume of 116.60K.
It is down -0.89% in the last 24 hours and down -14.62% over the past month.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
See More
Previous Close:
$1.12
Open:
$1.12
24h Volume:
116.60K
Relative Volume:
0.72
Market Cap:
$34.63M
Revenue:
$81,000
Net Income/Loss:
$-41.04M
P/E Ratio:
-0.8429
EPS:
-1.3169
Net Cash Flow:
$-30.69M
1W Performance:
-4.31%
1M Performance:
-14.62%
6M Performance:
-26.49%
1Y Performance:
+1.83%
1-Day Range:
$1.11
$1.18
1-Week Range:
$1.11
$1.1999
52-Week Range:
$1.06
$2.41
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.11 | 34.94M | 81,000 | -41.04M | -30.69M | -1.3169 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
Earnings Risk: What is the next catalyst for Actinium Pharmaceuticals Inc2025 Performance Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
Market Outlook: Is Actinium Pharmaceuticals Inc stock good for income investors2025 Big Picture & Low Drawdown Trading Techniques - baoquankhu1.vn
Profit Recap: Is Actinium Pharmaceuticals Inc stock trending bullish2025 Trade Ideas & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
US Market Wrap: Is now the right time to enter Actinium Pharmaceuticals IncDip Buying & Reliable Price Breakout Signals - baoquankhu1.vn
Head-To-Head Contrast: Actinium Pharmaceuticals (NYSE:ATNM) versus Avenue Therapeutics (NASDAQ:ATXI) - Defense World
Rally Mode: What is the next catalyst for Actinium Pharmaceuticals IncQuarterly Earnings Report & Smart Allocation Stock Reports - baoquankhu1.vn
What’s the outlook for Actinium Pharmaceuticals Inc.’s sector2025 Market WrapUp & Risk Controlled Swing Alerts - mfd.ru
Contrasting NexImmune (OTCMKTS:NEXI) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Analyzing Leap Therapeutics (NASDAQ:LPTX) and Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Retail Trends: Should I invest in IGM Biosciences Inc before earningsDay Trade & Reliable Price Breakout Alerts - baoquankhu1.vn
Reviewing Actinium Pharmaceuticals (NYSE:ATNM) & Aadi Bioscience (NASDAQ:AADI) - Defense World
How Actinium Pharmaceuticals Inc. (7AY1) stock responds to job market shiftsMarket Sentiment Indicators & Free Stay Ahead With Picks - bollywoodhelpline.com
Aug Selloffs: Is Actinium Pharmaceuticals Inc stock trending bullishJuly 2025 Market Mood & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Actinium Stock Gains Momentum from Clinical Trial Developments - AD HOC NEWS
Short Squeeze: What is the next catalyst for Actinium Pharmaceuticals IncProfit Target & Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Outlook: Will Actinium Pharmaceuticals Inc. stock outperform value stocks2025 Trade Ideas & Safe Capital Growth Plans - Bộ Nội Vụ
Why is Actinium Pharmaceuticals stock rising today? - MSN
Actinium Pharmaceuticals (NYSE:ATNM) & ProMetic Life Sciences (OTCMKTS:PFSCF) Head to Head Comparison - Defense World
Published on: 2026-01-09 08:22:12 - Улправда
Will Actinium Pharmaceuticals Inc. (Delaware) stock outperform foreign stocksQuarterly Growth Report & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
Why Actinium Pharmaceuticals Inc. stock remains on buy listsWeekly Stock Analysis & High Accuracy Trade Signal Alerts - Улправда
Can Actinium Pharmaceuticals Inc. stock hit analyst price targetsJuly 2025 Momentum & Breakout Confirmation Trade Signals - Улправда
How Actinium Pharmaceuticals Inc. (Delaware) stock valuation compares with sectorMarket Activity Report & Safe Entry Momentum Stock Tips - ulpravda.ru
Does Actinium Pharmaceuticals Inc. stock trade at a discount to peers2025 Performance Recap & Fast Moving Market Watchlists - Улправда
How geopolitical tensions affect Actinium Pharmaceuticals Inc. stockJuly 2025 Rallies & Capital Protection Trading Alerts - Улправда
Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (NY: ATNM - FinancialContent
Can Actinium Pharmaceuticals Inc. stock continue upward trendWeekly Profit Summary & Detailed Earnings Play Alerts - ulpravda.ru
Can Actinium Pharmaceuticals Inc. (Delaware) stock sustain revenue momentum2026 world cup usa national team semifinals goalkeepers set piece tactics odds analysis tactical review - ulpravda.ru
Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? - Yahoo Finance
Published on: 2025-12-20 18:07:18 - Улправда
Will Actinium Pharmaceuticals Inc. stock benefit from upcoming earnings reportsForecast Cut & Short-Term High Return Ideas - Улправда
Will Actinium Pharmaceuticals Inc. stock outperform value stocksJuly 2025 Patterns & Growth Oriented Trade Recommendations - Улправда
AstraZeneca’s Long-Term Isotope Deal Validates Actinium Pharmaceuticals’ Core Technology - AD HOC NEWS
Will Actinium Pharmaceuticals Inc. stock outperform Dow Jones index2025 Growth vs Value & Reliable Breakout Stock Forecasts - Улправда
How Actinium Pharmaceuticals Inc. (Delaware) stock responds to job market shiftsJuly 2025 Closing Moves & High Accuracy Buy Signal Tips - Улправда
AstraZeneca locks in long-term actinium-225 supply with Niowave - The Pharma Letter
Is Actinium Pharmaceuticals Inc. stock a top pick in earnings seasonJuly 2025 PostEarnings & Growth Oriented Trade Recommendations - Улправда
Published on: 2025-12-18 21:38:16 - Улправда
Actinium Pharmaceuticals stock rises after promising breast cancer therapy data - Investing.com Australia
Why Is Actinium Pharmaceuticals Stock Rising Today? - Menafn.com
Actinium (ATNM) Reveals Promising Preclinical Data for Novel Can - GuruFocus
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Br - PR Newswire
Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase 1/2 Trials in the U.S. and Australia - openPR.com
Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Down 0.7% – Here’s Why - Defense World
Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) Begins - openPR.com
Actinium Pharmaceuticals: Clinical Milestone and Promising Data Fuel Oncology Pipeline - AD HOC NEWS
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances - openPR.com
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances ATNM-400 Targeting STEAP-1 Across Prostate, Breast, and Lung Cancer - marketscreener.com
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):